ClinicalTrials.gg
CompletedNCT06045325Updated May 13, 2025Results posted

Assessment of Measurement Variability Across Automated Biometry Devices

An observational study in Myopia, sponsored by Berkeley Eye Center. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Berkeley Eye Center · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
204
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.

Enrollment
13th of 46
204 · median 91
Started
2023
with 30 others
Observational
48 of 342
6 open now
Registered
287th of 342
by date

Among the 342 studies in Myopia with a site in United States, this one is the 13th largest by enrollment of the 46 observational ones that give a count, is one of 31 that started in 2023, is one of 48 observational ones, and was the 287th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Myopia with a site in United States, or all of them as a file.
02

Study summary

This is a non-interventional prospective, comparative study of white-to-white, corneal thickness, and anterior chamber depth measurements as taken on the Orbscan II compared to the IOL Master 700 (Zeiss), IOL Master 500 (Zeiss), Atlas 9000 (Zeiss), Lenstar 900 (Haag-Streit), Argos (Alcon), iTrace (Tracey), Pentacam (Oculus), and manual calipers.

Read the detailed description

This is a non-interventional prospective, single center, bilateral, comparative study of white-to-white, corneal thickness, and anterior chamber depth measurements as taken on the Orbscan II compared to the IOL Master 700 (Zeiss), IOL Master 500 (Zeiss), Atlas 9000 (Zeiss), Lenstar 900 (Haag-Streit), Argos (Alcon), iTrace (Tracey), Pentacam (Oculus), and manual calipers. Additional biometric devices or external photography may be included as well.

03

Conditions studied

  • Myopia

Browse trials for

Keywords

  • -1.00 Diopter Spherical Equivalent
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Myopic patients with a spherical equivalent of at least -1.00D with healthy eyes and no prior eye surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults ages 18-50 years of age with healthy eyes and no prior ocular surgery
  2. At least -1.00 of myopia (spherical equivalent)
  3. Able to comprehend and willing to sign and consent and complete all required testing procedures
  4. Clear intraocular media

Exclusion criteria

Exclusion Criteria:

  1. Any corneal abnormality, other than regular corneal astigmatism (as determined by pre-operative testing) that in the opinion of the investigator would confound the outcome(s) of the study
  2. History of or current retinal conditions or predisposition to retinal conditions
  3. Amblyopia or strabismus in either eye
  4. History of or current anterior or posterior segment inflammation of any etiology
  5. Any form of neovascularization on or within the eye
  6. Glaucoma (uncontrolled or controlled with medication)
  7. Optic nerve atrophy
  8. Subjects with diagnosed degenerative eye disorders
  9. Subjects who have an acute or chronic disease or illness that would confound the results of this investigation in the opinion of the principal investigator (e.g. connective tissue disease, , atopic disease, etc.)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
204 participants (actual)
Patient registry
No

Groups and cohorts

  • Myopic -1.00D

    Myopic patients with a diopter of at least -1.00

    Diagnostic Test: Orbscan II · Diagnostic Test: IOL Master 700 · Diagnostic Test: IOL Master 500 · Diagnostic Test: Atlas 9000 · Diagnostic Test: Lenstar 900 · Diagnostic Test: Pentacam · Diagnostic Test: iTrace · Diagnostic Test: Argos · Diagnostic Test: Manual caliper measurement

Interventions

  • Diagnostic testOrbscan II

    Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

  • Diagnostic testIOL Master 700

    Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

  • Diagnostic testIOL Master 500

    Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

  • Diagnostic testAtlas 9000

    Diagnostic assessment to measure white-to-white.

  • Diagnostic testLenstar 900

    Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

  • Diagnostic testPentacam

    Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

  • Diagnostic testiTrace

    Diagnostic assessment to measure white-to-white and corneal thickness.

  • Diagnostic testArgos

    Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.

  • Diagnostic testManual caliper measurement

    Manual diagnostic assessment to measure white-to-white.

06

What researchers measure

Primary outcomes

  1. The Correlation of White-to-white Measurements Between Biometric Devices.

    The determination of the degree of correlation of white-to-white measurements between various biometric devices and the Orbscan II.

    Time frame: Day of visit

  2. The Correlation of Anterior Chamber Depth Measurements Between Biometric Devices.

    The determination of the degree of correlation of anterior chamber depth measurements between various biometric devices and the Orbscan II.

    Time frame: Day of visit

  3. The Correlation of Corneal Thickness Measurements Between Biometric Devices.

    The determination of the degree of correlation of corneal thickness measurements between various biometric devices and the Orbscan II.

    Time frame: Day of visit

07

Results

Posted May 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneMyopic -1.00D
Started204
Completed204
Not completed0

Outcome measures

PrimaryThe Correlation of White-to-white Measurements Between Biometric Devices.

The determination of the degree of correlation of white-to-white measurements between various biometric devices and the Orbscan II.

Time frame:
Day of visit
Reported as:
Number · Pearson correlation r
The Correlation of White-to-white Measurements Between Biometric Devices.
Pearson correlation rArgosAtlas 9000Manual CaliperIOLMaster 500IOLMaster 700iTraceLenstar LS900Pentacam AXL WavePentacam HR
The Correlation of White-to-white Measurements Between Biometric Devices.0.89 (0.87 to 0.91)0.65 (0.59 to 0.71)0.53 (0.46 to 0.60)0.60 (0.54 to 0.66)0.82 (0.78 to 0.85)0.78 (0.74 to 0.82)0.87 (0.84 to 0.89)0.84 (0.81 to 0.87)0.84 (0.81 to 0.87)
PrimaryThe Correlation of Anterior Chamber Depth Measurements Between Biometric Devices.

The determination of the degree of correlation of anterior chamber depth measurements between various biometric devices and the Orbscan II.

Time frame:
Day of visit
Reported as:
Number · Pearson correlation r
The Correlation of Anterior Chamber Depth Measurements Between Biometric Devices.
Pearson correlation rArgosIOLMaster 500IOLMaster 700Lenstar LS900Pentacam AXL WavePentacam HR
The Correlation of Anterior Chamber Depth Measurements Between Biometric Devices.0.91 (0.90 to 0.93)0.39 (0.31 to 0.47)0.33 (0.24 to 0.41)0.41 (0.33 to 0.49)0.95 (0.94 to 0.96)0.96 (0.96 to 0.97)
PrimaryThe Correlation of Corneal Thickness Measurements Between Biometric Devices.

The determination of the degree of correlation of corneal thickness measurements between various biometric devices and the Orbscan II.

Time frame:
Day of visit
Reported as:
Number · Pearson correlation r
The Correlation of Corneal Thickness Measurements Between Biometric Devices.
Pearson correlation rArgosIOLMaster 700Lenstar LS900Pentacam AXL WavePentacam HR
The Correlation of Corneal Thickness Measurements Between Biometric Devices.0.82 (0.78 to 0.85)0.80 (0.76 to 0.83)0.68 (0.63 to 0.73)0.68 (0.62 to 0.73)0.73 (0.68 to 0.77)

Adverse events

Collected over Day of visit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Argos0/204 (0%)0/204 (0%)0/204 (0%)
Atlas 90000/204 (0%)0/204 (0%)0/204 (0%)
Manual Caliper0/204 (0%)0/204 (0%)0/204 (0%)
IOLMaster 5000/204 (0%)0/204 (0%)0/204 (0%)
IOLMaster 7000/204 (0%)0/204 (0%)0/204 (0%)
iTrace0/204 (0%)0/204 (0%)0/204 (0%)
Lenstar LS9000/204 (0%)0/204 (0%)0/204 (0%)
Pentacam AXL Wave0/161 (0%)0/161 (0%)0/161 (0%)
Pentacam HR0/204 (0%)0/204 (0%)0/204 (0%)
Orbscan II0/204 (0%)0/204 (0%)0/204 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Myopic -1.00D
<=18 years0
Between 18 and 65 years204
>=65 years0
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Myopic -1.00D
Not disclosed204
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Myopic -1.00D
08

Study locations

1 site
  • Berkeley Eye Center
    Houston, Texas 77027, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Feb 2024, 6 months.

Results were first posted in May 2025, 1 year 2 months after primary completion.

Of 87 non-industry observational studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 90. This study's 6 months is below that.

Counting every sponsor, half of 96 studies reached it within 24 months; a quarter within 10 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 21, 2023
StartActual
Jul 25, 2023
Primary completionActual
Feb 16, 2024
CompletionActual
Feb 16, 2024
Results first posted
May 13, 2025
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06045325
Lead sponsor
Berkeley Eye Center
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jul 25, 2023
Primary completion
Feb 16, 2024
Completion
Feb 16, 2024
Results posted
May 13, 2025
Last update
May 13, 2025

Study contacts

Morgan Micheletti, MD
principal investigator · Berkeley Eye Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion